HALOZYME THERAPEUTICS, INC. (HALO) Cash flow
Market cap
$7.9B
P/E ratio
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Depreciation & amortization | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 3 | 7 | 11 | 10 |
| Stock-based compensation | 6 | 8 | 10 | 15 | 21 | 26 | 31 | 36 | 35 | 17 | 21 | 24 | 37 | 43 |
| Cash from operations | -34,350,425 | -64,329,296 | -49,339,479 | -48 | -37 | -50 | 134 | -49 | -85 | 55 | 299 | 240 | 389 | 479 |
| Capital expenditures | -828,508 | -1,412,585 | -2,297,518 | -1 | -2 | -3 | -1 | -5 | -4 | -3 | -1 | -5 | -15 | -11 |
| Cash from investing | -828,508 | -1,412,585 | -47,869,134 | -33 | 6 | -77 | -164 | 2 | -6 | 78 | -406 | -487 | -97 | -263 |
| Repurchases of common stock | - | - | - | - | - | - | - | - | 200 | 150 | 350 | 200 | 402 | 250 |
| Cash from financing | 5 | 113 | 25 | 115 | 13 | 151 | 132 | -64 | 153 | -106 | 78 | 362 | -408 | -219 |
| Free cash flow | ||||||||||||||
| FCF margin (%) |